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Psymmetric Dimethylarginine, L-Arginine, and
ndothelial Dysfunction in Essential Hypertension
rancesco Perticone, MD,* Angela Sciacqua, MD,* Raffaele Maio, MD,* Maria Perticone, MD,*
enke Maas, MD,† Rainer H. Boger, MD,† Giuseppe Tripepi, STAT TECH,‡ Giorgio Sesti, MD,*
armine Zoccali, MD‡
atanzaro and Reggio Calabria, Italy; and Hamburg-Eppendorf, Germany
OBJECTIVES We investigated the relationship between ADMA plasma levels and endothelium-dependent
vasodilation in 36 never-treated essential hypertensives and in 8 normotensive healthy subjects.
BACKGROUND It has been demonstrated that endothelium-dependent vasodilatation is impaired in essential
hypertension. The potential contribution of asymmetric dimethylarginine (ADMA) to
endothelial dysfunction of hypertensive humans has received poor attention.
METHODS Endothelial function was measured during intra-arterial infusion of acetylcholine (ACh),
alone and during co-infusion of L-arginine, and sodium nitroprusside at increasing doses.
Concentrations of ADMA and L-arginine in plasma were measured by high-performance
liquid chromatography.
RESULTS Hypertensive subjects had significantly higher ADMA and L-arginine plasma concentrations
than normotensive healthy controls; ACh-stimulated forearm blood flow (FBF) was
significantly reduced in hypertensive subjects in comparison to normotensive control subjects
(p  0.0001). Intra-arterial coinfusion of L-arginine induced a further significant enhance-
ment in ACh-stimulated vasodilation in hypertensive patients. In these, ADMA was strongly
and inversely associated with the peak increase in FBF. In a multivariate model, only ADMA
and L-arginine were independent correlates, accounting for 33.9% and 8.9% of the variability
in the peak FBF response to ACh (p  0.0001), respectively.
CONCLUSIONS The main finding in this study is that in essential hypertensives the L-arginine and
endogenous inhibitor of nitric oxide synthase, ADMA, are inversely related to endothelial
function. (J Am Coll Cardiol 2005;46:518–23) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.040Cardiology Foundation
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Tnatomical and functional integrity of the vascular en-
othelium is fundamental for preventing the appearance
nd progression of both coronary and extracoronary ath-
rosclerosis (1–3). Many vascular protective effects of the
ndothelium—including vasodilatation (1,4), inhibition of
onocyte and leukocyte adhesion (2,3), inhibition of plate-
et aggregation (2,5), modulation of vascular smooth muscle
ells, and fibroblasts proliferation (2,3,6)—are regulated by
itric oxide (NO), a short-lived molecule, produced by the
ndothelial enzyme nitric oxide synthase (e-NOS) from the
mino acid L-arginine (7).
It is now well established that major risk factors for
ardiovascular diseases (8–14) impact upon endothelial
unction by decreasing NO bioavailability. This condition,
hich occurs early in vascular disease, may be caused by
arious mechanisms including decreased NO synthesis,
ncreased NO degradation due to oxidative stress, or to
educed sensitivity to NO (2,4,15,16). With regard to the
rst mechanism, the activity of e-NOS may be inhibited by
ndogenous analogues of L-arginine such as asymmetric
From the *Internal Medicine and Cardiovascular Diseases Unit, Department of
edicina Sperimentale e Clinica “G. Salvatore,” University Magna Graecia of
atanzaro, Catanzaro, Italy; †Clinical Pharmacology Unit, Department of Pharma-
ology, University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany;
nd ‡CNR-IBIM, National Research Council-Institute of Biomedicine, Clinical
pidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio
alabria, Italy.f
Manuscript received January 26, 2005; revised manuscript received March 22,
005, accepted April 13, 2005.imethylarginine (ADMA) (17), which has been shown to
e increased in patients with chronic renal diseases (18), in
amilial hypercholesterolemia, and in a variety of clinical
ituations (19–22) including essential hypertension (23,24).
It has been consistently demonstrated that endothelium-
ependent vasodilatation is impaired in essential hyperten-
ion (8,9,14–16). This alteration has been attributed to
educed NO synthesis due to a specific defect in the
hosphoinositide pathway leading to activation of e-NOS
25), increased NO breakdown due to an increased produc-
ion of superoxide anions (8,15,16), and interaction with
ndothelium-derived factors (15). Even though the demon-
tration by Vallance that the vasoactive effects of NO
nhibition by ADMA in man (18) dates back to the early
990s, the potential contribution of ADMA to endothelial
ysfunction of hypertensive humans has received poor
ttention.
In this study we investigated the relationship between
DMA plasma levels and endothelium-dependent vasodi-
ation in a well-selected group of never-treated essential
ypertensives without cardiovascular complications and in a
ell-matched group of normotensive healthy subjects.
ETHODS
ypertensive subjects and healthy normotensive controls.
hirty-six hypertensive subjects, consecutively recruitedrom the Department of Experimental and Clinical Medi-
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August 2, 2005:518–23 ADMA and Endotheliumine of the University Hospital of Catanzaro, participated in
his study. All subjects were Caucasian and underwent
hysical examination and review of their medical history. To
e selected, patients had to have newly diagnosed essential
ypertension with a serum creatinine 1.5 mg/dl, have an
bsence of proteinuria on the dipstick test, and have never
eceived antihypertensive medications. Causes of secondary
ypertension were excluded by appropriate clinical and
iochemical tests. None of the patients had history or
linical evidence of coronary artery disease, valvular heart
isease, diabetes, hyperlipidemia, peripheral vascular dis-
ase, coagulopathy, or any disease predisposing to vasculitis
r Raynaud’s phenomenon. The control group was formed
y eight healthy normotensive volunteers well matched to
ypertensive patients as for age, body mass index (BMI),
nd Framingham risk factors.
The study was approved by the institutional ethics com-
ittee, and informed written consent was obtained from
ach subject in accordance with principles of the Declara-
ion of Helsinki.
tudy protocol. Blood sampling and vascular function
ere performed at 9 AM after subjects had fasted overnight,
ith the subjects lying supine in a quiet, air-conditioned
oom (22°C to 24°C). Participants were instructed to
ontinue their regular diet. Caffeine, alcohol, and smoking
ere stopped at least 24 h before the study. Readings of
linic blood pressure (BP) were obtained in the left arm of
he supine patients, after 5 min of quiet rest, with a mercury
phygmomanometer. Three BP readings were taken on
hree separate occasions at least two weeks apart. Baseline
P values were the average of last two of the three
onsecutive measurements obtained at intervals of 3 min.
atients with a clinic BP 140 mm Hg systolic and/or 90
m Hg diastolic were defined as hypertensive.
emodynamic studies. Forearm volume was determined
y water displacement. Under local anesthesia and sterile
onditions, a 20-gauge polyethylene catheter (Vasculon 2,
D, Franklin Lakes, New Jersey) was inserted into the
rachial artery of the nondominant arm for evaluation of BP
Baxter Healthcare Corp., Deerfield, Illinois) and for drug’s
nfusion. This arm was elevated above the level of the right
trium, and a mercury-filled silastic strain-gauge was placed
Abbreviations and Acronyms
ACh  acetylcholine
ADMA asymmetric dimethylarginine
BMI  body mass index
BP  blood pressure
e-NOS  endothelial nitric oxide synthase
FBF  forearm blood flow
HR  heart rate
NO  nitric oxide
SNP  sodium nitroprusside
VR  vascular resistancen the widest part of the forearm. The strain-gauge was 0onnected to a plethysmograph (model EC-4, D.E. Ho-
anson, Issaquah, Washington) calibrated to measure the
ercent change in volume; this was connected to a chart
ecorder to obtain the forearm blood flow (FBF) measure-
ents. A cuff placed on the upper arm was inflated to 40
m Hg with a rapid cuff inflator (model E-10 Hokanson)
o exclude venous outflow from the extremity. A wrist cuff
as inflated to BP values 1 min before each measurement to
xclude the hand blood flow. The antecubital vein of the
pposite arm was cannulated. The FBF was measured as the
lope of the change in the forearm volume. The mean of at
east three measurements was obtained at each time point.
orearm vascular resistance (VR), expressed in units, was
alculated by dividing mean BP by FBF.
cetylcholine (ACh) and sodium nitroprusside (SNP)
nfusions. A standardized protocol, previously described by
anza et al. (8), and subsequently adopted by our group
13,14), was employed for the present study. All participants
nderwent measurement of FBF and BP during intra-
rterial infusion of saline, ACh, and SNP at increasing
oses. Acetylcholine (Sigma, Milan, Italy) was diluted with
aline immediately before infusion. Sodium nitroprusside
Malesci, Florence, Italy) was diluted in 5% glucose solution
mmediately before each infusion and protected from light
ith aluminum foil. All participants rested 30 min after
rtery cannulation to reach a stable baseline before data
ollection; measurements of FBF and VR were repeated
very 5 min until stable. Endothelium-dependent and
ndothelium-independent vasodilation were assessed by a
ose-response curve to intra-arterial ACh infusions (7.5, 15,
nd 30 g/ml1/min1, each for 5 min) and SNP infusions
0.8, 1.6, and 3.2 g/ml1/min1, each for 5 min), respec-
ively. The infusions of ACh and SNP were carried out in
andom order to avoid any bias related to the sequence of
rug infusion. The drug infusion rate, adjusted for forearm
olume of each subject, was 1 ml/min.
-arginine infusion. After a stabilization period of 20 to
0 min, resting FBF was measured again, and a dose-
esponse curve to intrabrachial ACh administration was
erformed during the co-infusion of L-arginine, the sub-
trate for NO synthesis, at a constant dose of 200 mol/
in, starting 10 min before ACh administration and
ontinuing throughout.
etermination of ADMA and L-arginine. Samples were
tored in pre-chilled vacutainers containing edetic acid,
laced immediately on ice, and centrifuged within 30 min at
°C; plasma was stored at 80°C until required. Concen-
rations of ADMA and L-arginine in plasma were measured
y high-performance liquid chromatography, by pre-
olumn derivatization with o-phthalaldehyde, after removal
f plasma samples with carboxylic acid solid-phase extrac-
ion cartridges (Varian, Harbor City, California). The
oefficients of variation were 5.2% within-assay and 5.5%
etween-assay; the detection limit of the assay was
.1 mol/l1.
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ADMA and Endothelium August 2, 2005:518–23tatistical analysis. Differences for clinical and biological
ata were compared by using unpaired Student t test and
hi-square test. The vasodilatory responses to ACh and
NP were compared by analysis of variance for repeated
easurements and, when analysis was significant, the Tukey
est was applied. Simple linear regression analysis was
erformed to assess the relationship between the peak
ercent increase in FBF in response to ACh infusion,
DMA, and L-arginine. The independent relationship
etween ADMA, L-arginine, and the hemodynamic re-
ponse to ACh in hypertensive subjects was also tested by
ackward multiple regression analysis. This model retained
ust two variables as statistically significant and was there-
ore adequately powered (10 subjects per covariate) to test
he hypothesis. Parametric data are reported as mean SD.
ignificant differences were assumed to be at p  0.05. All
omparisons were performed using the statistical package
PSS 10.0 for Windows (SPSS Inc., Chicago, Illinois).
ESULTS
ll participants completed the protocol. Baseline demo-
raphic, hemodynamic, and humoral characteristics are
ummarized in Table 1. There were no significant differ-
nces in age, total cholesterol, high-density lipoprotein
holesterol, glucose, triglycerides, BMI, and FBF between
ontrol subjects and hypertensive patients. All patients were
ormotolerant, and there were no smokers. Vascular resis-
ance was higher (p  0.05) in hypertensive subjects than
ormotensive healthy controls. According to inclusion cri-
eria, systolic and diastolic BP values were significantly (p
.0001) lower in control subjects in comparison with hy-
ertensive patients.
DMA and L-arginine concentrations. Hypertensive
ubjects had significantly higher ADMA plasma concentra-
ion than normotensive healthy controls (0.59  0.14
mol/l vs. 0.40  0.09 mol/l, p  0.0001). Plasma
able 1. Characteristics of the Study Population
Hypertensives
(n  36)
Normotensives
(n  8) p Value
ender (males/females) 28/8 4/4 0.247
ge (yrs) 44.2  8.8 44.5  5.8 0.927
ody mass index (kg/m2) 27.2  2.8 26.2  4.0 0.404
eart rate (beats/min) 74.5  8.5 75.8  11.2 0.714
ystolic BP (mm Hg) 155.9  8.3 124.4  4.1 0.000
iastolic BP (mm Hg) 93.1  7.3 69.1  4.8 0.000
ulse pressure (mm Hg) 62.8  7.8 55.4  6.0 0.016
asting glucose (mg/dl) 92.4  8.4 90.4  12.5 0.581
otal cholesterol (mg/dl) 194.6  25.3 186.7  29.0 0.444
DL cholesterol (mg/dl) 126.4  27.4 121.1  31.4 0.632
DL cholesterol (mg/dl) 48.0  10.4 46.0  8.3 0.614
riglycerides (mg/dl) 100.6  21.9 98.1  35.4 0.797
reatinine (mg/dl) 0.87  0.10 0.83  0.11 0.312
BF (m · 100 ml1 of
tissue · min1)
3.36  0.28 3.49  0.23 0.229
ascular resistance (U) 33.2  4.3 26.3  2.5 0.000P  blood pressure; FBF  forearm blood flow; HDL  high-density lipoprotein;
DL  low-density lipoprotein.
f
p-arginine concentrations (mol/l) were 47.4 18.5 in the
ypertensive group and 26.0  8.1 in normotensive control
ubjects (p  0.003). An increase in plasma ADMA
esulted in a higher, but not significant, mean L-arginine/
DMA ratio in hypertensive than in normotensive subjects
79.4  21.8 vs. 69.0  25.5, p  0.243). In Figure 1 we
eport the relationship between L-arginine and ADMA in
he whole population.
ndothelium-dependent and -independent vasodilation.
aseline FBF did not differ in the two groups (Table 1).
ntra-arterial infusion of ACh caused a significant dose-
ependent increase in FBF and decrease in forearm VR in
oth groups. The FBF values at the three incremental doses
f ACh were 7.5  1.4, 11.5  2.3, and 22.3  5.9 ml/100
l1 of tissue/min1 and 6.3 1.9, 9.4 2.5, and 15.3 4.7
l/100 ml1 of tissue/min1 for normotensive and hyperten-
ive patients, respectively (Fig. 2). The VR values at the
hree incremental doses of ACh were 21.2  7.4, 16.9 
igure 1. Relationship between L-arginine (L-Arg) and asymmetric di-
ethylarginine (ADMA) in both normotensive subjects (NTs) (open
ircles) and hypertensive patients (HTs) (solid circles). In the whole
opulation (r  0.626; p  0.0001) and in the HT group (r  0.545; p 
.001), the two covariates resulted linearly correlated; no relationship was
ound in the NT group.
igure 2. Forearm blood flow (FBF) increase during infusion of acetyl-
holine (ACh). As shown, ACh-stimulated FBF was significantly reduced
n hypertensive subjects (HTs) in comparison to normotensive control
NTs) subjects. Intra-arterial coinfusion of L-arginine (L-Arg) induced a
urther significant enhancement in ACh-stimulated vasodilation in HT
atients.
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August 2, 2005:518–23 ADMA and Endothelium.5, and 8.7  2.6 U and 26.5  8.1, 19.7  6.9, and
1.2  2.5 U for normotensive subjects and hypertensive
atients, respectively. Thus, ACh-stimulated FBF was sig-
ificantly reduced in hypertensive subjects in comparison to
ormotensive control subjects (p  0.0001). In both groups
P and heart rate (HR) remained unchanged during intra-
rterial infusion of ACh.
Incremental doses of intra-arterial infusion of SNP in-
uced a significant increase in FBF as well as a decrease in
orearm VR in both normotensive subjects and hypertensive
atients. At the highest dose of SNP, the FBF percent
ncrements (17.7  2.3 vs. 17.3  4.1 ml/100 ml1 of
issue/min1) as well as the VR (4.9  1.6 vs. 6.6  1.6 U)
ecrements from baseline did not differ between the two
roups. In both groups intra-arterial infusion of SNP did
ot cause any significant change in BP or HR.
ffects of L-arginine on endothelial function. As shown
n Figure 2, intra-arterial coinfusion of L-arginine induced
further significant enhancement—above resting levels—in
Ch-stimulated vasodilation in hypertensive patients (area
nder the curve  664  70 vs. 402  151; p  0.0001).
slight, but significant, increase was observed also in
ormotensive subjects (area under the curve  688  84 vs.
56  108; p 0.016). Comparison of area under the curve
n normotensive and hypertensive subjects was not signifi-
ant (p  0.402).
The L-arginine coinfusion did not change arterial BP or
R in both hypertensives and control subjects.
orrelation analyses. As shown in Figure 3, in hyperten-
ive subjects ADMA was strongly and inversely associated
ith the peak increase in ACh-stimulated FBF. Of note,
lso L-arginine was inversely related with the same hemo-
ynamic response (Table 2). L-arginine and ADMA were
irectly related (r  0.545, p  0.001) (Fig. 1). No such
elationships were found in normotensive subjects (p values
rom 0.06 to 0.260).
To further analyze the independent contribution of
DMA and L-arginine to the peak FBF response to ACh,
e constructed a backward multivariate model testing
DMA, L-arginine, and Framingham risk factors listed in
able 1. This multivariate model retained only ADMA and
-arginine as independent correlates of the outcome mea-
igure 3. In this figure the correlation between asymmetric dimethylargi-T
ine (ADMA) levels and the peak increase in acetylcholine-stimulated
orearm blood flow is reported in hypertensive patients.ure accounting for 33.9% and 8.9% of the variability in the
eak FBF response to ACh (p  0.0001), respectively. In
articular, ACh-stimulated FBF decreases by 2.4% for every
mol of L-arginine, and by 35.8% for every 0.1 mol of
DMA.
ISCUSSION
he main finding in this study is that in essential hyper-
ensives the endogenous inhibitor of e-NOS ADMA is
nversely related to endothelial function as measured by the
eak hemodynamic response to ACh. Such relationship
ccurs in a range of ADMA values within the boundaries of
he normal range. A companion, unexpected, finding in this
tudy is that circulating L-arginine is directly related to
lasma ADMA and, like plasma ADMA, it is inversely
elated to endothelial function.
The importance of ADMA as an endogenous inhibitor of
-NOS is now well established (26–28). Elegant studies in
ealthy volunteers convincingly demonstrated that intrave-
ous ADMA infusion at a dose resulting in pathophysio-
ogical concentrations augments peripheral and renovascular
esistance and arterial pressure (22). High plasma ADMA
oncentration was observed in the presence of traditional or
merging cardiovascular risk factors (e.g., hyperhomocys-
einemia) (18–21,29), inducing endothelial dysfunction in
ome of these conditions (30–33).
The relationship between ADMA and essential hyper-
ension has been scarcely explored. Plasma ADMA levels
ere measured only in four studies and coherently found to
e higher in hypertensive patients (23,24) than in normo-
ensive healthy subjects (22), particularly in salt-sensitive
ndividuals (34). However, in none of these studies the
elationship between ADMA and endothelial function was
ested. In one study, urinary nitrate excretion was reduced
oncomitantly with elevated ADMA plasma levels in pa-
ients with essential hypertension, suggesting that systemic
O production was impaired in these patients (24).
Remarkably, we found that plasma ADMA, though
ithin the limits of the physiologic concentration, was
igher in hypertensives than in normotensive subjects and
nversely related with ACh-stimulated FBF. This relation-
hip was independent of potential confounders because, in a
ultivariate model, ADMA, but not other risk factors,
etained an independent association with such a response.
able 2. Correlational Analysis Between Forearm Blood Flow as
ependent Variable, ADMA, L-Arginine, and
-Arginine/ADMA
Hypertensives
(n  36) p Value
Normotensives
(n  8) p Value
DMA 0.583 0.007 0.601 0.057
-arginine 0.567 0.000 0.018 0.483
-arginine/
ADMA
0.281 0.049 0.268 0.260
DMA  asymmetric dimethylarginine.hus, our study provides the first demonstration that in
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ADMA and Endothelium August 2, 2005:518–23ssential hypertension relatively higher ADMA plasma
evels impair endothelium-dependent vasodilation.
The cause of high plasma ADMA concentration in
ssential hypertension is presently unknown. Increased
hear stress triggers ADMA synthesis, and high ADMA in
ypertension may therefore be an epiphenomenon of high
P (35). Alternatively, high ADMA may result from
educed catabolic rate secondary to dimethylaminohydrolase
nhibition brought about by oxidative stress, a well-known
eature of human hypertension (15,26). Independently of
he mechanism responsible for the ADMA increase, our
ata suggest that this increase is causally involved in
ndothelial dysfunction; in keeping with this, impaired FBF
esponse to ACh in hypertensive subjects reverts to normal
uring coinfusion of L-arginine, an amino acid that com-
etes with ADMA at level of catalytic sites of e-NOS.
An unexpected and intriguing finding in this study is
hat, again within the limits of the normal range, plasma
-arginine was higher in essential hypertensives than in
ormotensive subjects. This alteration has been very re-
ently noted in another study and attributed to an inhibition
f L-arginine transport via system y, a phenomenon that
ay also limit NO synthesis (36). Furthermore, we ob-
erved that plasma L-arginine concentration was directly
elated to plasma ADMA concentration. L-arginine metab-
lism is complex and highly regulated (37). This amino acid
s synthesized from citrulline by sequential action of cyto-
olic enzymes arginosuccinate synthetase and lyase (38).
rginase activity may be another determinant of L-arginine
lasma concentrations (39). Animal studies indeed suggest
hat expression or activity of arginases, which degrade
-arginine, may be altered in hypertension as well (40,41).
n this perspective it can be speculated that that relatively
igher L-arginine in essential hypertensives is a counter-
egulatory response aimed at compensating NO inhibition
y ADMA, a possibility supported by the direct relationship
inking plasma L-arginine and ADMA. Although the two
nterpretations are not mutually exclusive, the inverse rela-
ionship between plasma L-arginine and maximal response
o ACh, obtained by us, would support the hypothesis that
-arginine transport or metabolism is altered in essential
ypertension. On the other hand, the fact that intra-arterial
nfusion of L-arginine restores endothelial function clearly
ndicates that disturbed transport of this amino acid into the
ndothelial cell is completely surmounted at high infusion
ates.
In conclusion, there is a subtle increase in plasma
DMA in essential hypertensives. Such an increase seems
unctionally relevant because relatively higher plasma
DMA levels underlie endothelial dysfunction. Plasma
-arginine concentration in hypertensive patients parallels
lasma ADMA concentration, and relatively higher
-arginine levels are associated with compromised endothe-
ial function, a phenomenon in keeping with the hypothesis
hat in essential hypertension the transport of this amino
cid is altered.
2eprint requests and correspondence: Dr. Francesco Perticone,
epartment of Medicina Sperimentale e Clinica, Policlinico
ater Domini, Via Tommaso Campanella, 88100 Catanzaro,
taly. E-mail: perticone@unicz.it.
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